Statements (60)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
chemical compound
|
| gptkbp:analyzes |
HPLC
statistical analysis performed IND_filed |
| gptkbp:application |
antitumor agent
|
| gptkbp:chemicalFormula |
white crystalline solid
amide C12H15N3O2 |
| gptkbp:clinicalTrials |
Phase 1
multiple sites results published narrow therapeutic window |
| gptkbp:collaborations |
gptkb:ABC_Pharmaceuticals
|
| gptkbp:community_service |
overall survival
specific biomarker identified |
| gptkbp:compatibleWith |
inhibitor of cell proliferation
|
| gptkbp:composedOf |
multi-step synthesis
|
| gptkbp:constructedIn |
high yield
|
| gptkbp:contraindication |
headache
|
| gptkbp:dissolved |
soluble in DMSO
|
| gptkbp:dosageForm |
once daily
|
| gptkbp:drugInterdiction |
dose-dependent effects
minimal interactions favorable pharmacokinetics |
| gptkbp:environmentalImpact |
low toxicity
|
| gptkbp:financial_aid |
stable at room temperature
|
| gptkbp:followedBy |
ongoing follow-up study
|
| gptkbp:hasPopulation |
adult patients
|
| gptkbp:healthcare |
ongoing recruitment
|
| gptkbp:historicalResearch |
further studies planned
|
| https://www.w3.org/2000/01/rdf-schema#label |
WPC-652
|
| gptkbp:impact |
6 months
|
| gptkbp:isATypeOf |
123456-78-9
|
| gptkbp:isDiscussedIn |
promising results in animal studies
|
| gptkbp:marketSegment |
not available on the market
|
| gptkbp:model |
mouse_model
|
| gptkbp:notableEvent |
improved quality of life
|
| gptkbp:origin |
N-(4-(dimethylamino)phenyl)-2-(1H-imidazol-1-yl)acetamide
|
| gptkbp:patentCitation |
effective against tumor cells
|
| gptkbp:patentStatus |
patented
|
| gptkbp:productionCompany |
under investigation
|
| gptkbp:regulatoryCompliance |
not approved yet
|
| gptkbp:relatedPatent |
gptkb:WPC-651
|
| gptkbp:releaseYear |
2010
|
| gptkbp:research |
government grant
|
| gptkbp:researchField |
pharmaceutical chemistry
|
| gptkbp:researchInterest |
gptkb:XYZ_University
international collaboration Journal of Medicinal Chemistry approved by ethics committee |
| gptkbp:responseTime |
high response rate
|
| gptkbp:route |
oral
|
| gptkbp:safetyFeatures |
acceptable safety profile
|
| gptkbp:scientificName |
specific receptor
|
| gptkbp:sideEffect |
nausea
|
| gptkbp:storage |
cool and dry place
|
| gptkbp:targets |
cancer
protein kinase |
| gptkbp:triggerType |
inhibition of specific kinases
|
| gptkbp:weight |
233.27 g/mol
|